Brief: Eloxx Pharmaceuticals Reports Q1 Loss Per Share Of $0.13
10/05/2022 13:11
May 10 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL
AND
OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
* QTRLY LOSS PER SHARE $0.13
* ON TRACK TO START HUMAN PHASE 1 STUDY IN 2022 WITH ZKN-013
FOR
TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
* CASH AND EQUIVALENTS EXPECTED TO BE SUFFICIENT TO FUND
OPERATIONS INTO THE SECOND QUARTER OF 2023
* Q2 EARNINGS PER SHARE VIEW $-0.12 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX1JzGd6
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome